Drug Interactions between Bexxar and Neoral
This report displays the potential drug interactions for the following 2 drugs:
- Bexxar (iodine i 131 tositumomab)
- Neoral (cyclosporine)
Interactions between your drugs
There were no interactions found in our database between Bexxar and Neoral - however, this does not necessarily mean no interactions exist. Always consult with your doctor or pharmacist.
- Bexxar is in the following drug classes: CD20 monoclonal antibodies, therapeutic radiopharmaceuticals.
- Bexxar is used to treat Non-Hodgkin's Lymphoma.
- Neoral is a member of the drug class calcineurin inhibitors.
- Neoral is used to treat the following conditions:
Drug and food interactions
Applies to: Neoral (cyclosporine)
Grapefruit and grapefruit juice can increase the levels of cycloSPORINE in your body and should generally not be consumed during treatment. High blood levels of cycloSPORINE can lead to increased risk of serious side effects on kidney, liver, and nervous system functions. If you regularly consume grapefruits or grapefruit juice, you should be monitored for side effects and/or changes in cycloSPORINE levels. However, do not increase or decrease the amount of grapefruit products in your diet without first talking to your doctor. You should also take cycloSPORINE on a consistent schedule with regard to time of day and relation to meals. Let your doctor know if you experience fever, rash, nausea, vomiting, abdominal pain, loss of appetite, dark urine, jaundice (yellowing of the skin or eyes), decreased urination, excessive thirst, swelling, weight gain, dizziness, fatigue, weakness, headache, blurred vision, numbness/burning/tingling in the hand and feet, tremors, or convulsions, as they may be symptoms caused by excessive effects of cycloSPORINE.
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
|Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.|
|Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.|
|Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.|
|No interaction information available.|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.